Sequoia Financial Advisors LLC Grows Holdings in Edwards Lifesciences Co. (NYSE:EW)

Sequoia Financial Advisors LLC grew its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 17.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,078 shares of the medical research company’s stock after buying an additional 1,176 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Edwards Lifesciences were worth $598,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in EW. GSA Capital Partners LLP acquired a new position in Edwards Lifesciences in the third quarter worth $481,000. Empowered Funds LLC boosted its position in Edwards Lifesciences by 10.7% during the 3rd quarter. Empowered Funds LLC now owns 24,032 shares of the medical research company’s stock worth $1,586,000 after acquiring an additional 2,324 shares during the period. Swiss National Bank grew its stake in shares of Edwards Lifesciences by 0.5% in the third quarter. Swiss National Bank now owns 1,788,600 shares of the medical research company’s stock worth $118,030,000 after purchasing an additional 8,300 shares in the last quarter. Quest Partners LLC acquired a new position in shares of Edwards Lifesciences during the third quarter valued at $406,000. Finally, W.G. Shaheen & Associates DBA Whitney & Co bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $7,290,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $70.67 on Tuesday. The stock has a 50 day moving average of $71.68 and a two-hundred day moving average of $70.34. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $41.55 billion, a P/E ratio of 10.14, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

EW has been the topic of a number of research reports. Piper Sandler boosted their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. The Goldman Sachs Group raised their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Finally, Morgan Stanley boosted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $79.95.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 400 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.48, for a total transaction of $27,792.00. Following the transaction, the vice president now owns 22,588 shares in the company, valued at $1,569,414.24. This represents a 1.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,189,770.56. The trade was a 16.83 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 51,303 shares of company stock valued at $3,715,776. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.